GOLM1 and metabolic dysfunction-associated steatohepatitis: As GP73 is a biomarker associated with liver disease progression, it may be proposed for its potential role in monitoring therapeutic responses in MASH patients as a non-invasive and safe diagnostic practice suitable for large populations.